|
|
Volumn 5, Issue 4, 2013, Pages 513-517
|
|
Antibodies to watch in 2013: Mid-year update
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALIROCUMAB;
ALZUMAB;
AMG 145;
BENDAMUSTINE;
BRODALUMAB;
CHLORAMBUCIL;
EVOLOCUMAB;
FARLETUZUMAB;
GEVOKIZUMAB;
ITOLIZUMAB;
KHK 4827;
MABP1;
MEPOLIZUMAB;
MONOCLONAL ANTIBODY;
MOXETUMOMAB PASUDOTOX;
NAPTUMOMAB ESTAFENATOX;
OBINUTUZUMAB;
PERTUZUMAB;
PLACEBO;
RAMUCIRUMAB;
RESLIZUMAB;
RILOTUMUMAB;
RITUXIMAB;
ROMOSOZUMAB;
SIRUKUMAB;
TABALUMAB;
TAXANE DERIVATIVE;
TILDRAKIZUMAB;
TRASTUZUMAB;
TRASTUZUMAB EMTANSINE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
USTEKINUMAB;
VEDOLIZUMAB;
XILONIX;
ACUTE CORONARY SYNDROME;
ASTHMA;
BREAST CANCER;
BREAST METASTASIS;
BRONCHITIS;
CACHEXIA;
CANCER SURVIVAL;
CHRONIC LYMPHATIC LEUKEMIA;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
COLORECTAL CANCER;
CROHN DISEASE;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG MARKETING;
DRUG SAFETY;
EOSINOPHILIA;
EOSINOPHILIC ASTHMA;
EOSINOPHILIC BRONCHITIS;
ESOPHAGEAL ADENOCARCINOMA;
HAIRY CELL LEUKEMIA;
HUMAN;
HYPERCHOLESTEROLEMIA;
HYPEREOSINOPHILIC SYNDROME;
HYPERLIPIDEMIA;
KIDNEY CARCINOMA;
LIVER CELL CARCINOMA;
LUNG ADENOCARCINOMA;
LUNG NON SMALL CELL CANCER;
MULTIPLE CYCLE TREATMENT;
MULTIPLE MYELOMA;
MULTIPLE SCLEROSIS;
NONHODGKIN LYMPHOMA;
OVARY CARCINOMA;
OVERALL SURVIVAL;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
POSTMENOPAUSE OSTEOPOROSIS;
PROGRESSION FREE SURVIVAL;
PSORIASIS;
PSORIASIS VULGARIS;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
RHEUMATOID ARTHRITIS;
STOMACH ADENOCARCINOMA;
STOMACH CANCER;
SYSTEMIC LUPUS ERYTHEMATOSUS;
ULCERATIVE COLITIS;
UVEITIS;
CANCER;
CLINICAL STUDIES;
IMMUNOLOGICAL DISORDERS;
MONOCLONAL ANTIBODIES;
ANIMALS;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS, PHASE III AS TOPIC;
HUMANS;
|
|
EID: 84880128705
PISSN: 19420862
EISSN: 19420870
Source Type: Journal
DOI: 10.4161/mabs.24990 Document Type: Review |
|
Times cited : (79)
|
|
References (5)
|
